Reverse Transcriptase Inhibitors

"Reverse Transcriptase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.

Descriptor ID	D018894
MeSH Number(s)	D27.505.519.389.675.850 D27.505.954.122.388.077.750
Concept/Terms	Reverse Transcriptase Inhibitors Reverse Transcriptase Inhibitors Inhibitors, Reverse Transcriptase

Below are MeSH descriptors whose meaning is more general than "Reverse Transcriptase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Nucleic Acid Synthesis Inhibitors [D27.505.519.389.675]
Reverse Transcriptase Inhibitors [D27.505.519.389.675.850]
Therapeutic Uses [D27.505.954]
Anti-Infective Agents [D27.505.954.122]
Antiviral Agents [D27.505.954.122.388]
Anti-Retroviral Agents [D27.505.954.122.388.077]
Reverse Transcriptase Inhibitors [D27.505.954.122.388.077.750]

Below are MeSH descriptors whose meaning is related to "Reverse Transcriptase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Reverse Transcriptase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Reverse Transcriptase Inhibitors" by people in this website by year, and whether "Reverse Transcriptase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 39 publications over 18 distinct years, with a maximum of 6 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	1	0	1
2001	1	1	2
2003	4	2	6
2004	3	0	3
2006	2	0	2
2007	1	2	3
2008	4	0	4
2009	1	0	1
2010	0	1	1
2011	3	1	4
2012	1	0	1
2013	1	0	1
2015	2	0	2
2016	1	0	1
2017	2	1	3
2019	0	1	1
2021	0	2	2
2023	0	1	1

Below are the most recent publications written about "Reverse Transcriptase Inhibitors" by people in Profiles.

Gbadamosi SO, Boyce G, Trepka MJ, Edwards RJ. The Burden of Pretreatment HIV Drug Resistance in Trinidad and Tobago. AIDS Res Hum Retroviruses. 2024 04; 40(4):189-197.

View in: PubMed
Rebeiro PF, Jenkins CA, Bian A, Lake JE, Bourgi K, Moore RD, Horberg MA, Matthews WC, Silverberg MJ, Thorne J, Mayor AM, Lima VD, Palella FJ, Saag MS, Althoff KN, Gill MJ, Wong C, Klein MB, Crane HM, Marconi VC, Shepherd BE, Sterling TR, Koethe JR. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. Clin Infect Dis. 2021 10 05; 73(7):e2234-e2242.

View in: PubMed
Kline MDA, Daniels C, Xu X, Sunil T, Ganesan A, Agan BK, Colombo RE, Kronmann KC, Blaylock JM, Okulicz JF, Markelz AE. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV. Mil Med. 2021 02 26; 186(3-4):279-285.

View in: PubMed
Gojanovich GS, Shikuma CM, Milne C, Libutti DE, Chow DC, Gerschenson M. Subcutaneous Adipocyte Adenosine Triphosphate Levels in HIV Infected Patients. AIDS Res Hum Retroviruses. 2020 01; 36(1):75-82.

View in: PubMed
Beymer MR, Kofron RM, Tseng CH, Bolan RK, Flynn RP, Sayles JM, Perez MJ, Jordan WC, Landovitz RJ. Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County. Int J STD AIDS. 2018 05; 29(6):557-562.

View in: PubMed
SahBandar IN, Samonte G, Telan E, Siripong N, Belcaid M, Schanzenbach D, Leano S, Chagan-Yasutan H, Hattori T, Shikuma CM, Ndhlovu LC. Ultra-Deep Sequencing Analysis on HIV Drug-Resistance-Associated Mutations Among HIV-Infected Individuals: First Report from the Philippines. AIDS Res Hum Retroviruses. 2017 Nov; 33(11):1099-1106.

View in: PubMed
Cranston RD, Lama JR, Richardson BA, Carballo-Di?guez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu CS, Galaska B, Jacobson CE, Parikh UM, Marzinke MA, Hendrix CW, Johnson S, Piper JM, Grossman C, Ho KS, Lucas J, Pickett J, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu AY, Mayer KH, Zorrilla C, Schwartz JL, Rooney J, McGowan I. MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clin Infect Dis. 2017 03 01; 64(5):614-620.

View in: PubMed
Leger P, Chirwa S, Turner M, Richardson DM, Baker P, Leonard M, Erdem H, Olson L, Haas DW. Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race. Pharmacogenet Genomics. 2016 10; 26(10):473-80.

View in: PubMed
Tashima KT, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, Johnson VA, Klingman KL, Ritz J, Hodder S, Santana JL, Wilkin T, Haubrich RH. HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Ann Intern Med. 2015 Dec 15; 163(12):908-17.

View in: PubMed
Kumari N, Kulkarni AA, Lin X, McLean C, Ammosova T, Ivanov A, Hipolito M, Nekhai S, Nwulia E. Inhibition of HIV-1 by curcumin A, a novel curcumin analog. Drug Des Devel Ther. 2015; 9:5051-60.

View in: PubMed

People

Explore

Similar Concepts

Top Journals